These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32605584)

  • 1. Alcohol use disorders and the risk of progression of liver disease in people with hepatitis C virus infection - a systematic review.
    Llamosas-Falcón L; Shield KD; Gelovany M; Manthey J; Rehm J
    Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):45. PubMed ID: 32605584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study.
    Schwarzinger M; Baillot S; Yazdanpanah Y; Rehm J; Mallet V
    J Hepatol; 2017 Sep; 67(3):454-461. PubMed ID: 28396173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
    J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study.
    McDonald SA; Hutchinson SJ; Bird SM; Mills PR; Robertson C; Dillon JF; Williams T; Goldberg DJ
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):49-57. PubMed ID: 19773667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness.
    Innes HA; Hutchinson SJ; Barclay S; Cadzow E; Dillon JF; Fraser A; Goldberg DJ; Mills PR; McDonald SA; Morris J; Stanley A; Hayes P;
    Hepatology; 2013 Feb; 57(2):451-60. PubMed ID: 22961861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.
    Smith DJ; Combellick J; Jordan AE; Hagan H
    Int J Drug Policy; 2015 Oct; 26(10):911-21. PubMed ID: 26298331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of hepatic fibrosis, cirrhosis, and mortality with cholecystectomy in patients with hepatitis C virus infection.
    Martin DJ; Weideman R; Crook T; Brown G
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):181-6. PubMed ID: 26566061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis.
    Chen Y; Ji H; Shao J; Jia Y; Bao Q; Zhu J; Zhang L; Shen Y
    Dig Dis Sci; 2020 Jul; 65(7):1940-1950. PubMed ID: 31758432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C and alcohol: interactions, outcomes, and implications.
    Bhattacharya R; Shuhart MC
    J Clin Gastroenterol; 2003 Mar; 36(3):242-52. PubMed ID: 12590237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C and hepatitis B-related mortality in Spain.
    García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
    Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.
    Thein HH; Yi Q; Dore GJ; Krahn MD
    Hepatology; 2008 Aug; 48(2):418-31. PubMed ID: 18563841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
    Mallet V; Beeker N; Bouam S; Sogni P; Pol S;
    J Hepatol; 2021 Oct; 75(4):848-855. PubMed ID: 33992699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
    Perz JF; Armstrong GL; Farrington LA; Hutin YJ; Bell BP
    J Hepatol; 2006 Oct; 45(4):529-38. PubMed ID: 16879891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
    Poynard T; Bedossa P; Opolon P
    Lancet; 1997 Mar; 349(9055):825-32. PubMed ID: 9121257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection.
    Udompap P; Mannalithara A; Heo NY; Kim D; Kim WR
    J Hepatol; 2016 May; 64(5):1027-1032. PubMed ID: 26809112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands.
    van Santen DK; Schim van der Loeff MF; Cartier van Dissel J; Martens JPD; van der Valk M; Prins M
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1168-1176. PubMed ID: 30028776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
    PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence.
    Verbaan H; Widell A; Bondeson L; Andersson K; Eriksson S
    J Viral Hepat; 1998 Jan; 5(1):43-51. PubMed ID: 9493516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.